Application of an iPSC‐Derived Organoid Model for Localized Scleroderma Therapy (Adv. Sci. 16/2022)
Jie Ma(Beijing University of Posts and Telecommunications), Ling Leng(Tianjin University of Traditional Chinese Medicine), Mansheng Li(Beijing Proteome Research Center), Biyou Li(Anhui Medical University), Dunqin Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruiyuan Cao, Shuyang Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wěi Li(Shougang (China)), Jun Li(Jiangnan University), Yujie Wang(Pharmacology Research Institute), Xiao Li(Beijing Proteome Research Center), Wu Zhong(Hainan Modern Women and Children's Hospital), Yunping Zhu(Beijing Technology and Business University), Qiyu Zhang, Junyi Jiang(Beijing Proteome Research Center), Zhihong Wu(Academy of Medical Sciences), Luye Lv(National Defense University)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Outcome over seven years of healthy adults with and without subjective cognitive impairment
|Alzheimer s & Dementia|2010|582
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416